ArQule Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
ArQule (ARQL) PT Raised to $8 at Oppenheimer
March 8, 2019 9:11 AM ESTOppenheimer analyst Hartaj Singh raised the price target on ArQule (NASDAQ: ARQL) to $8.00 (from $7.00) while maintaining a Outperform rating following the company's 4Q report. Results were in line with Oppenheimer's estimates and expectations. Singh has updated the model for 2019, with estimates in line with... More
Needham & Company Reiterates Bullish View on ArQule (ARQL) as Partial Response Seen in C481S Mutant Patient with ARQ-531
March 7, 2019 1:44 PM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $7 price target on ArQule (NASDAQ: ARQL) after a partial response was observed in ibrutinib refractory C481S mutant patient with ARQ-531.
"ArQule reported that the first patient treated in the current 7th... More
ArQule (ARQL) Surges 40% Following Results, Update
March 7, 2019 9:27 AM ESTArQule (NASDAQ: ARQL) is gaining 40% in pre-open trade following results and update.
... MoreArQule (ARQL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Guidance Below Consensus
March 7, 2019 7:03 AM ESTArQule (NASDAQ: ARQL) reported Q4 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $2.94 million versus the consensus estimate of $1.82 million.
ARQ 531, our potent and reversible dual inhibitor of both wild-type and C481S-mutant BTK. Successfully progressed recruitment in our ongoing phase 1 dose escalation trial in 2018, enrolling over 20 patients at 7 dose cohorts ranging from 5mg to 65mg QD. Data from this trial was presented at 3 major conferences (AACR, EHA, ASH) in 2018 and demonstrated a good safety profile, profound target engagement and encouraging signs of dose-dependent clinical... More